Definitive Contract HHSN261201100073C
Award Date
9/15/11
Potential Completion Date
12/14/12
Potential Value
$148K
Federal Agency
National Cancer Institute
Awardee
Detroit R&D, Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bloomfield Hills, MI 48301, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
14
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract is for the development of glycosylation-specific research under SBIR Topic 294, with a ceiling value of $148,569. SBIR contracts are set-aside for small businesses to engage in research and development for the government. This Phase I contract represents the initial research and feasibility...
This is a Small Business Innovation Research (SBIR) contract awarded by the National Institutes of Health's (NIH) National Cancer Institute (NCI) to Glycoscientific, L.L.C., a small business research company. The contract is for the development of glycosylation-specific research reagents, including antibodies and aptamers, under SBIR Topic 294 Phase I. The contract has a ceiling value of $149,951 and was awarded on a firm fixed-price basis. This contract was set aside for total small business...
<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Biotex, Inc. The contract is for the development of glycosylation-specific research, with a ceiling value of $149,919.00 and a completion date of October 14, 2012. The contract is a definitive contract with a firm fixed-price pricing type. This SBIR Phase I action is a set-aside for small businesses.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Glycohub, Inc., a woman-owned small business. The contract is for the delivery of chemically defined glycosphingolipid head groups, with a total ceiling value of $298,447.00 and a completion date of December 30, 2014. As an SBIR Phase I contract, this represents the initial research and development effort to explore the feasibility of the proposed technology....
This is a $289,828.00 SBIR Phase I contract awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Nicolalde R&D LLC, a minority-owned, self-certified small disadvantaged business. The contract is a firm fixed-price definitive contract with a completion date of November 30, 2021. The SBIR (Small Business Innovation Research) Program Phase I award indicates this contract is for early-stage research and development activities. As a...
<p>This is a $199,969 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Accelerated Medical Diagnostics, Inc. The contract is for "OTHER FUNCTIONS - R & D BIOMEDICAL (BASIC RESEARCH)" and has a firm fixed price pricing type with a completion date of September 30, 2016. As an SBIR Phase I award, this contract supports early-stage research and development activities.</p>
<p>This is a $299,813 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Hylapharm LLC, a self-certified small disadvantaged business, under the SBIR Program Phase I. The contract is for the development of "Targeted Nanoparticle Treatment for Breast Cancer Stem Cells." This contract has a Total Small Business set-aside designation. The contract has an ultimate completion date of September 17, 2016.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract, valued at $185,116, is a firm-fixed-price definitive contract for research and development work. The contract was awarded on September 24, 2010 and has an ultimate completion date of June 23, 2011. As an SBIR Phase I contract, it is focused on the early-stage feasibility study of a...
<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Pharmaseq, Inc. The contract is for the development of an "Antibody Array for Cancer Detection" under SBIR Topic 236. The contract has a firm fixed price ceiling value of $150,000.00 and a period of performance ending on March 29, 2009. The contract is designated as a Total Small Business Set-Aside.</p>
This is a Phase II Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Siamab Therapeutics, Inc. The purpose of the contract is to develop technologies to characterize glycan moieties of glycoproteins in order to enhance the diagnostic capability of protein-based biomarkers. The specific goals include expanding the number of features for an existing sialic acid glycan array, optimizing the serum assay protocol,...